Eli Lilly’s recent launch of Mounjaro in India has sparked a surge in inquiries about weight-loss solutions. The new drug, aimed at managing obesity, has captured significant attention, reflecting a growing demand for effective weight management options in the country.
Canada has added a commonly prescribed blood pressure medication to its drug shortages website, raising concerns among healthcare professionals about potential impacts on patient care. Authorities urge patients to consult with their physicians for alternatives.
In a recent announcement, former President Donald Trump renewed threats of tariffs on Indian pharmaceutical imports, marking a sudden shift that has negatively impacted Indian pharma stocks. Investors reacted swiftly, reversing the brief respite enjoyed by the sector.
Australia’s trade tensions with the Trump administration escalated over affordable medicines. The U.S. criticized Australia’s pharmaceutical pricing policies, arguing they undermined fair trade, while Australia defended its system aimed at ensuring low-cost access to essential drugs.
Eli Lilly is set to introduce its weight-loss drug in emerging markets this year, aiming to address rising obesity rates. The launch follows successful outcomes in developed regions, positioning Lilly to expand its global footprint in the competitive weight management sector.
A recent investigation by BBC reveals that an Indian pharmaceutical company is significantly contributing to West Africa’s escalating opioid crisis. The report highlights alarming practices, including the production and distribution of potent opioids, raising concerns about public health and regulatory oversight in the region.
